Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: Long-term results from a phase 2 trial

110Citations
Citations of this article
79Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Light-chain (AL) amyloidosis remains incurable despite recent therapeutic advances. Given the activity of the lenalidomidealkylating agent combination in myeloma, we designed this phase 2 trial of lenalidomide, cyclophosphamide, and dexamethasone in AL amyloidosis. Thirty-five patients, including 24 previously untreated, were enrolled. Nearly one-half of the patients had cardiac stage III disease and 28% had ≥ 3 organs involved. The overall hematologic response (≥ partial response [PR]) rate was 60%, including 40% with very-good partial response or better. Using serum-free light chain for assessing response, 77% of patients had a hematologic response. Organ responses were seen in 29% of patients and were limited to those with a hematologic response. The median hematologic progressionfree survival was 28.3 months, and the median overall survival was 37.8 months. Hematologic toxicity was the predominant adverse event, followed by fatigue, edema, and gastrointestinal symptoms. A grade 3 or higher toxicity occurred in 26 patients (74%) including ≥ grade 3 hematologic toxicity in 16 patients (46%) and ≥ grade 3 nonhematologic toxicity in 25 patients (71%). Seven patients (20%) died on study, primarily because of advanced disease. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) is an effective combination for treatment of AL amyloidosis and leads to durable hematologic responses as well as organ responses with manageable toxicity. The trial was registered at www.clinicaltrials.gov (NCT00564889). © 2012 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Kumar, S. K., Hayman, S. R., Buadi, F. K., Roy, V., Lacy, M. Q., Gertz, M. A., … Dispenzieri, A. (2012). Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: Long-term results from a phase 2 trial. Blood, 119(21), 4860–4867. https://doi.org/10.1182/blood-2012-01-407791

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free